-
Hong Kong 2021 award ceremony held
Time of Update: 2022-01-13
The Chief Executive of the Hong Kong Special Administrative Region, Carrie Lam, presented the honours and awards to the 157 recipients at the ceremony on the first day .
Chairman Zheng Xiangling was awarded the "Silver Bauhinia" star on the spot .
-
Facing the challenge of "no drug available", a new wave of RSV drugs under development welcomes progress
Time of Update: 2022-01-13
Globally, there are a number of preventive vaccines and innovative drugs for respiratory diseases caused by RSV that are already in the clinical development stage, which is expected to usher in a new dawn .
-
Huadong Medicine: Daptomycin for injection of its subsidiary obtains US FDA approval
Time of Update: 2022-01-13
In 2015, Huadong Medicine's daptomycin was approved to be listed in China and became the company's blockbuster product in the field of anti-infection .
-
Dolutegravir's first imitation: Qilu takes the lead in launching clinical trials
Time of Update: 2022-01-12
According to the Insight database, there are currently 3 compound preparations approved for marketing of dolutegravir in addition to single drugs worldwide .
cn/v5/home/)At present, apart from Qilu, no other companies have applied for the start of clinical trials of dolutegravir generic drugs .
-
Illegal purchases of medicines and purchases of Angong Bezoar pharmacies lost 110,000
Time of Update: 2022-01-12
A pharmacy bought 131 boxes of Angong Niuhuang Pills (valued at RMB 16,240, an average of RMB 124 per box) from an individual, and suffered a direct loss of RMB 116,240 and an average of RMB 887 for a
-
Hebo Pharma appoints Xu Weihao as chief strategy officer
Time of Update: 2022-01-12
It was learned on December 3 that Hebo Medicine announced that it had officially appointed Xu Weihao as Chief Strategy Officer, reporting directly to Dr.
-
Sudden injection drug recall!
Time of Update: 2022-01-12
According to the FDA announcement that this batch of enoxaparin sodium injection was shipped to customers in September and October 2021, at least one month has passed since the risk was discovered on December 1 .
-
The Aduhelm controversy has not yet ended the Bojian Tecfidera generic drug patent case has fallen again
Time of Update: 2022-01-12
S. Court of Appeals refused to restore a key patent for Biogen's multiple sclerosis Tecfidera .
S. Court of Appeals for the Federal Circuit ruled that the District Court for the Northern District of West Virginia had "no obvious error" when it declared the Tecfidera patent invalid in June last year .
-
FDA refuses to approve the listing of ponabrin, Wanchun Pharmaceutical Co., Ltd. plummets 60%, Hengrui drops slightly by 1.92%
Time of Update: 2022-01-12
At the same time, Hengrui Medicine stated that, in accordance with the "Panabulin Product Cooperation Agreement", the company has paid Dalian Wanchun a down payment of 200 million yuan and has not yet carried out any clinical research on Panabulin .
-
Many of my friends have won the bid!
Time of Update: 2022-01-12
On October 21, Zhejiang Province formally issued the "Announcement on the Second Batch of Drugs Concentrated Procurement of Zhejiang Public Medical Institutions" (purchasing number ZJYPCG-2021-1), announcing the official start of the second batch of mass procurement .
-
Chairman of Stellite Hu Jian resigns and Hu Jinsheng returns
Time of Update: 2022-01-12
On December 7, Stellite issued an announcement stating that Hu Jian, the chairman of the company, proposed to the board of directors to resign as chairman due to personal reasons.
-
Shanghai Pharmaceutical Holding Subsidiary Rivaroxaban Tablets Approved for Production
Time of Update: 2022-01-12
On December 8, Shanghai Pharmaceuticals issued an announcement stating that the rivaroxaban tablets of its subsidiary, Changzhou Pharmaceutical Factory, received the "Drug Registration Certificate" issued by the State Drug Administration, and the drug was approved for production .
-
The State Food and Drug Administration issued a notice that 2 batches of Quantai Pharmaceuticals did not meet the requirements
Time of Update: 2022-01-12
1. According to the inspection of Hubei Provincial Institute of Drug Supervision and Inspection, a batch of Atractylodes japonicus produced by Hebei Quantai Pharmaceutical Co.
According to the inspection by Qinghai Provincial Drug Inspection and Testing Institute, a batch of wood incense produced by Hebei Quantai Pharmaceutical Co.
-
Fuhong Hanlius' ``bevacizumab'' biosimilar drug approved in China
Time of Update: 2022-01-12
According to a press release issued by Fuhong Henlius earlier, the approved marketing application for this product is aimed at the treatment of patients with advanced, metastatic or recurrent non-small cell lung cancer and metastatic colorectal cancer .
-
The next generation of BRAF inhibitors into the brain!
Time of Update: 2022-01-12
ABM-1310, developed by Bichen Pharmaceutical, has shown its ideal advantages in blood-brain barrier penetration in pre-clinical studies .
-
Beida Pharmaceuticals BPI-361175 tablets obtained the U.S. FDA New Drug Clinical Trial Approval Notice
Time of Update: 2022-01-12
On December 5, Betta Pharmaceuticals issued an announcement stating that the company's application for clinical trials of BPI-361175 tablets has been approved by the US FDA and is intended to be used for the treatment of non-small cell lung cancer carrying EGFRC797S mutations and other EGFR-related mutations .
-
Merck's new crown oral drug Molnupiravir emergency authorization application approved
Time of Update: 2022-01-12
Molnupiravir reduces the risk of hospitalization or death by approximately 50%However, on November 26, Merck and Ridgeback announced updated clinical data for the new crown oral drug Molnupiravir for the treatment of mild to moderate new crowns .
-
The results of the national talks are released. The full analysis of key products involves Hengrui, Rongchang, and Geli Pharmaceuticals, etc.
Time of Update: 2022-01-12
, Fluzoparil Capsules, Hetropopaethanolamine Tablets, and Azilsartan Tablets; Two new drugs are included in the 2021 medical insurance list by Golly Pharmaceuticals and Rongchang Biologics, namely danorevir sodium tablets and ravi hydrochloride Davir tablets, vedicitumumab for injection, and taltacept for injection .
-
The fourth generation EGFR inhibitor!
Time of Update: 2022-01-12
ArticleMedicine GuanlanOn December 5, Betta Pharmaceuticals issued a press release stating that it has received a new drug clinical trial approval notice issued by the US FDA, agreeing to its fourth-generation EGFR inhibitor BPI-361175 tablets for the treatment of EGFR C797S mutations and others Drug clinical trial application for non-small cell lung cancer with EGFR-related mutations .
-
The New General Rules of Pharmacopoeia for Nitrosamines USP <1469> will be officially implemented on December 1st
Time of Update: 2022-01-12
Based on experience or literature reports, the general rules summarize the main sources of nitrosamines:Under certain conditions and in the presence of certain reagents, solvents, raw materials and processing aids, the processing of bulk drugs is carried out .
